MedTrace Logo

Immune Response and Risk of Serious Infection to SARS-Cov2

NCT04410432 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2026-02-02

No results posted yet for this study

Summary

To date, nearly 2 million people, including at least 100,000 in France, have been infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). This infection is very heterogeneous in nature, ranging from asymptomatic forms to acute respiratory distress syndrome patterns in 6.1% of cases, leading to an estimated overall mortality of 5.2%.

Apart from age, few risk factors for a pejorative evolution have been identified: arterial hypertension, diabetes, cardiovascular history, obesity and chronic respiratory pathology in particular. The median incubation period is 5 days and the median time between the appearance of the first symptoms and the onset of hypoxia requiring admission to intensive care is 7 to 12 days. The mechanisms involved in the occurrence of these secondary worsening patterns are unclear. One hypothesis is that it is related to an inappropriate inflammatory response rather than a direct cytopathic effect of the virus. The objective of this study is to measure the intensity of the T lymphocyte response in patients hospitalized for Cov2 SARS infection in order to determine whether the intensity of the response is associated with worsening of symptoms.

Conditions

  • SARS Cov2, Immune Response

Interventions

BIOLOGICAL

Blood sample collection

Additional blood volumes taken during a routine care blood test: * 1 dry tube 5 mL for isolation and freezing of serum * 1 x 5 mL EDTA tube to isolate and freeze plasma * 8 heparinized 6 mL tubes for flow cytometry study

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Dijon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-29
Primary Completion
2021-01-21
Completion
2021-01-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04410432 on ClinicalTrials.gov